HEP B, C DIABETES PACKAGE at Chughtai Lab

Understanding the HEP B, C DIABETES PACKAGE at Chughtai Lab

The HEP B, C DIABETES PACKAGE at Chughtai Lab is a comprehensive, clinically designed diagnostic panel that screens for three of the most prevalent and chronic health conditions in Pakistan: Hepatitis B, Hepatitis C, and Diabetes Mellitus. This specialized package combines essential serological markers and metabolic indicators to provide a thorough assessment of an individual’s hepatic and metabolic health. By evaluating these parameters simultaneously, healthcare providers can identify early-stage infections and metabolic disorders, allowing for timely intervention and management. Chughtai Lab, a premier diagnostic network headquartered in Lahore, Pakistan, utilizes state-of-the-art automated laboratory technology to ensure the highest level of precision and reliability for this critical screening panel.

Hepatitis B and Hepatitis C are viral infections that primarily target the liver, leading to acute or chronic inflammation. Over time, undetected viral hepatitis can progress to severe liver damage, including hepatic fibrosis, cirrhosis, and hepatocellular carcinoma (liver cancer). Concurrently, Diabetes Mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The clinical intersection between chronic viral hepatitis and diabetes is highly significant; chronic liver disease can impair glucose metabolism, leading to hepatogenous diabetes, while pre-existing diabetes can accelerate the progression of liver fibrosis in patients with Hepatitis B or C. Therefore, screening for these conditions together offers immense diagnostic value, particularly for high-risk populations, individuals with a family history of metabolic disease, or those with potential exposure to blood-borne pathogens.

The HEP B, C DIABETES PACKAGE at Chughtai Lab evaluates key biomarkers, including the Hepatitis B Surface Antigen (HBsAg) to detect active Hepatitis B infection, the Anti-HCV antibody to screen for exposure to the Hepatitis C virus, Fasting Blood Glucose (FBG) to assess acute glycemic status, and Glycated Hemoglobin (HbA1c) to determine the average blood glucose concentration over the preceding eight to twelve weeks. Together, these tests provide a comprehensive clinical picture of a patient’s metabolic and hepatic health, serving as a vital tool for preventive medicine, routine health evaluations, and chronic disease management.

Clinical Procedure: What to Expect

Patient Preparation

Appropriate patient preparation is essential to guarantee the clinical accuracy of the metabolic components within the HEP B, C DIABETES PACKAGE at Chughtai Lab. Patients must adhere to the following preparation guidelines prior to sample collection:

• Fasting Requirement: Patients must fast for a minimum of 8 hours and a maximum of 12 hours before the blood draw. Fasting is strictly required for the Fasting Blood Glucose (FBG) component of the package. During this period, no food, caloric beverages, tea, coffee, or juices should be consumed.
• Hydration: Drinking plain, unflavored water is highly encouraged during the fasting period. Adequate hydration maintains blood volume and makes venipuncture easier and more comfortable.
• Medication Management: Patients should consult their referring physician regarding their routine medications. While most maintenance medications can be taken with water, glucose-lowering drugs or insulin may need to be adjusted or delayed until after the blood sample is collected to prevent hypoglycemia.
• Avoid Alcohol and Strenuous Exercise: Patients should refrain from consuming alcohol and engaging in vigorous physical activity for at least 24 hours before the test, as these factors can transiently alter blood glucose levels and liver enzyme profiles.
• Timing: It is highly recommended to schedule the blood collection during the early morning hours to align with the natural diurnal rhythm of blood glucose and to minimize the discomfort of prolonged fasting.

During the Procedure

The collection of the blood sample for the HEP B, C DIABETES PACKAGE at Chughtai Lab is a standard, safe, and minimally invasive phlebotomy procedure performed by certified and experienced phlebotomists. The entire process takes approximately five to ten minutes and follows strict aseptic protocols:

• Patient Identification and Verification: The phlebotomist will verify the patient’s identity using official identification and confirm compliance with the fasting requirements.
• Positioning: The patient is comfortably seated in a specialized phlebotomy chair. The arm is extended and supported to ensure stability during the venipuncture.
• Site Selection and Preparation: The phlebotomist inspects the antecubital fossa (the crease of the elbow) to locate a suitable vein, typically the median cubital vein. The selected site is thoroughly cleansed with an antiseptic swab (70% isopropyl alcohol) and allowed to air dry to prevent hemolysis and contamination.
• Tourniquet Application: A soft tourniquet is applied a few inches above the selected site to increase venous pressure, making the vein more visible and palpable.
• Venipuncture: A sterile, single-use needle attached to a vacuum collection system is gently inserted into the vein. The phlebotomist collects the blood into specific color-coded tubes: a gold-top or red-top tube for serological testing (Hepatitis B and C) and a grey-top (sodium fluoride) or purple-top (EDTA) tube for glucose and HbA1c testing.
• Tourniquet Release and Needle Removal: Once the required volume of blood is collected, the tourniquet is released, the needle is smoothly withdrawn, and immediate pressure is applied to the puncture site with a sterile cotton ball or gauze.
• Post-Procedure Care: A small adhesive bandage is applied over the puncture site. The patient is advised to keep the bandage on for at least one hour and to avoid heavy lifting with that arm for the rest of the day. The labeled tubes are then prepared for transport to the laboratory under controlled temperature conditions.

When is a HEP B, C DIABETES PACKAGE Performed?

Screening High-Risk Populations in Pakistan

The HEP B, C DIABETES PACKAGE at Chughtai Lab is frequently performed as a screening tool for individuals at elevated risk for viral hepatitis or metabolic disorders. In Pakistan, viral hepatitis remains a major public health concern due to historical challenges with medical equipment sterilization, unsafe therapeutic injections, and lack of awareness. Simultaneously, Pakistan has one of the highest prevalences of diabetes globally. Physicians recommend this package for individuals with a history of blood transfusions, dental procedures, surgical interventions, or those with a family history of type 2 diabetes, allowing for early detection before clinical symptoms manifest.

Investigating Metabolic and Hepatic Symptoms

This diagnostic panel is indicated when a patient presents with overlapping clinical symptoms that suggest metabolic dysfunction or hepatic impairment. Common symptoms include chronic fatigue, unexplained weight loss, increased thirst (polydipsia), frequent urination (polyuria), persistent lethargy, mild abdominal discomfort in the upper right quadrant, or unexplained skin changes. Because the early stages of chronic Hepatitis B, Hepatitis C, and diabetes can be entirely asymptomatic, presenting with any of these non-specific symptoms warrants a comprehensive laboratory evaluation to rule out these major chronic conditions.

Routine Preventive Health Evaluations

Preventive healthcare is crucial for maintaining long-term wellness and reducing the burden of chronic diseases. The HEP B, C DIABETES PACKAGE at Chughtai Lab is an integral component of routine annual health checkups for adults, particularly those over the age of 30. Detecting prediabetes or early-stage viral hepatitis during a routine checkup enables patients and healthcare providers to implement lifestyle modifications, dietary changes, and medical therapies that can prevent the progression to full-blown diabetes, liver cirrhosis, or liver failure.

Pre-Surgical and Occupational Health Screening

Many healthcare institutions, corporate organizations, and international visa processing centers require comprehensive health screenings prior to employment, surgery, or travel. The HEP B, C DIABETES PACKAGE at Chughtai Lab serves as a standard pre-surgical screening panel to ensure the safety of both the patient and the surgical team by identifying active viral infections that could complicate recovery or pose an occupational transmission risk. It is also widely utilized for occupational health clearances to verify the health status of employees in high-responsibility sectors.

Clinical Workup for Cardiovascular and Endocrine Risk Factors

Endocrinologists and cardiologists frequently request this package for patients presenting with metabolic syndrome, obesity, hypertension, or dyslipidemia. There is a strong pathophysiological link between insulin resistance, cardiovascular disease, and non-alcoholic fatty liver disease (NAFLD). Identifying underlying diabetes or chronic viral hepatitis in these patients is critical, as both conditions significantly escalate cardiovascular risk and complicate the management of endocrine disorders. The results of this package guide clinicians in formulating comprehensive, multi-specialty treatment plans.

What Does a HEP B, C DIABETES PACKAGE Detect?

The HEP B, C DIABETES PACKAGE at Chughtai Lab is designed to detect and evaluate a wide spectrum of clinical parameters and pathological states, including:

• Active Hepatitis B Infection: Detects the presence of Hepatitis B Surface Antigen (HBsAg) in the blood, indicating an active acute or chronic infection.
• Hepatitis C Exposure: Detects antibodies against the Hepatitis C virus (Anti-HCV), indicating either a current active infection or a past resolved infection.
• Fasting Hyperglycemia: Measures elevated blood glucose levels after fasting, which is a primary diagnostic indicator for diabetes and prediabetes.
• Impaired Fasting Glucose (IFG): Identifies early-stage metabolic dysfunction where fasting glucose levels are higher than normal but not yet in the diabetic range.
• Long-Term Glycemic Control (HbA1c): Evaluates the percentage of glycated hemoglobin, reflecting the average blood sugar levels over the past two to three months.
• Prediabetes: Detects HbA1c levels between 5.7% and 6.4%, signaling a high risk of developing type 2 diabetes.
• Type 2 Diabetes Mellitus: Confirms diabetic-range glycemic markers (HbA1c of 6.5% or higher, or fasting glucose of 126 mg/dL or higher).
• Chronic Viral Hepatitis Carrier State: Helps identify asymptomatic carriers of Hepatitis B who may unknowingly transmit the virus.
• Risk of Hepatic Fibrosis: Identifies patients with chronic viral infections who require further staging for liver scarring and fibrosis.
• Insulin Resistance: Correlates elevated fasting glucose and HbA1c with clinical signs of insulin resistance.
• Risk of Diabetic Complications: Evaluates glycemic control to assess the risk of microvascular and macrovascular complications, such as neuropathy, retinopathy, and nephropathy.
• Co-morbid Metabolic and Viral States: Identifies patients suffering from both viral hepatitis and diabetes, a combination that accelerates liver disease.
• Need for Confirmatory PCR Testing: Detects reactive viral serology, indicating the immediate need for quantitative HBV DNA or HCV RNA PCR testing.
• Efficacy of Ongoing Diabetic Treatment: Monitors blood glucose and HbA1c levels in patients already diagnosed with diabetes to assess treatment success.
• Potential for Hepatogenous Diabetes: Detects metabolic impairment secondary to chronic liver inflammation and cirrhosis.
• Immune Status and Exposure History: Distinguishes between individuals who have never been exposed to Hepatitis C and those who require further diagnostic workup.

Turnaround Time and Report Access at Chughtai Lab

Chughtai Lab is renowned for its highly efficient laboratory workflow, advanced automated systems, and commitment to rapid turnaround times. For the HEP B, C DIABETES PACKAGE at Chughtai Lab, routine results are typically processed, verified by consultant pathologists, and made available within 12 to 24 hours of sample collection. This rapid reporting ensures that patients and referring physicians can make timely clinical decisions without unnecessary delay.

Patients can access their diagnostic reports through multiple convenient digital channels. Chughtai Lab provides an online patient portal on their official website, where reports can be viewed and downloaded using the patient’s lab ID and password. Additionally, reports are sent directly via WhatsApp and SMS alerts as soon as they are finalized. For a comprehensive experience, patients can utilize the Chughtai Lab Mobile App to track their test status, view historical lab data, and download PDF reports. Physical copies of the reports can also be collected from any of the numerous Chughtai Lab collection centers located across Lahore and other cities in Pakistan.

HEP B, C DIABETES PACKAGE Findings Overview

Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Hepatitis B Surface Antigen (HBsAg)	Non-Reactive (Negative)	Reactive (Positive) – Indicates active acute or chronic Hepatitis B infection.
Anti-HCV Antibody	Non-Reactive (Negative)	Reactive (Positive) – Indicates exposure to Hepatitis C; requires confirmatory PCR.
Fasting Blood Glucose (FBG)	70 – 99 mg/dL	100 – 125 mg/dL (Impaired Fasting Glucose); 126 mg/dL or higher (Suspected Diabetes).
Glycated Hemoglobin (HbA1c)	Less than 5.7%	5.7% – 6.4% (Prediabetes); 6.5% or higher (Diabetes Mellitus).
Liver Function Correlation	Normal metabolic clearance	Impaired glucose tolerance secondary to chronic hepatic inflammation.
Viral Transmission Risk	No active viral shedding detected	High risk of transmission (if HBsAg or HCV RNA is active).
Glycemic Control Status	Optimal glucose homeostasis	Poor glycemic control, insulin resistance, or metabolic syndrome.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for HEP B, C DIABETES PACKAGE?

• Experienced Healthcare Professionals: Testing is supervised and reports are verified by highly qualified consultant pathologists and clinical scientists.
• Patient-Focused Care: Dedicated staff members ensure a comfortable, safe, and professional experience during sample collection.
• Quality Diagnostic Services: Chughtai Lab adheres to stringent international quality control standards, ensuring highly accurate and reproducible results.
• Professional Reporting: Clear, structured, and comprehensive report formats that are easy for both patients and clinicians to interpret.
• Modern Diagnostic Approach: Utilizing fully automated, state-of-the-art immunoassay and clinical chemistry analyzers.
• Comfortable Environment: Modern, clean, and hygienic collection centers designed to provide a stress-free patient experience.
• Convenient Location: An extensive network of collection centers across Lahore and nationwide, making diagnostic services highly accessible.
• Commitment to Accurate Diagnosis: Continuous participation in external quality assurance programs to maintain the highest diagnostic integrity.